Syed Faaiz Enam

Syed Faaiz Enam

Auto-generated profile, based on publicly available information

Syed Faaiz Enam

Department of Biomedical Engineering, Duke University, Durham, NC 27708, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2015 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
LKLohitash Karumbaiah
Lohitash Karumbaiah
SESyed Faaiz Enam
Syed Faaiz Enam
ABAshley C. Brown
Ashley C. Brown
TSTarun Saxena
Tarun Saxena
MBMartha I. Betancur
Martha I. Betancur
RBRavi V. Bellamkonda
Ravi V. Bellamkonda

20 June 2020 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
SESyed Faaiz Enam
Syed Faaiz Enam
SKSajidur Rahman Kader
Sajidur Rahman Kader
NBNicholas Bodkin
Nicholas Bodkin
JLJohnathan G. Lyon
Johnathan G. Lyon
MCMark Calhoun
Mark Calhoun
RBRavi Venkat Bellamkonda
Ravi Venkat Bellamkonda
Background: Appropriately modulating inflammation after traumatic brain injury (TBI) may prevent disabilities for the millions of those inflicted annually. In TBI, cellular mediators of inflammation, including macrophages and microglia, possess a range of phenotypes relevant for an immunomodulatory therapeutic approach. It is thought that early phenotypic modulation of these cells will have a cascading healing effect. In fact, an anti-inflammatory, “M2-like” macrophage phenotype after TBI has been associated with neurogenesis, axonal regeneration, and improved white matter integrity (WMI). There already exist clinical trials seeking an M2-like bias through mesenchymal stem/stromal cells (MSCs). However, MSCs do not endogenously synthesize key signals that induce robust M2-like phenotypes such as interleukin-4 (IL-4).Methods: To enrich M2-like macrophages in a clinically relevant manner, we augmented MSCs with synthetic IL-4 mRNA to transiently express IL-4. These IL-4 expressing MSCs (IL-4 MSCs) were characterized for expression and functionality and then delivered in a modified mouse TBI model of closed head injury. Groups were assessed for functional deficits and MR imaging. Brain tissue was analyzed through flow cytometry, multi-plex ELISA, qPCR, histology, and RNA sequencing.Results: We observed that IL-4 MSCs indeed induce a robust M2-like macrophage phenotype and promote anti-inflammatory gene expression after TBI. However, here we demonstrate that acute enrichment of M2-like macrophages did not translate to improved functional or histological outcomes, or improvements in WMI on MR imaging. To further understand whether dysfunctional pathways underlie the lack of therapeutic effect, we report transcriptomic analysis of injured and treated brains. Through this, we discovered that inflammation persists despite acute enrichment of M2-like macrophages in the brain.Conclusion: The results demonstrate that MSCs can be engineered to induce a stronger M2-like macrophage response in vivo. However, they also suggest that acute enrichment of only M2-like macrophages after diffuse TBI cannot orchestrate neurogenesis, axonal regeneration, or improve WMI. Here, we also discuss our modified TBI model and methods to assess severity, behavioral studies, and propose that IL-4 expressing MSCs may also have relevance in other cavitary diseases or in improving biomaterial integration into tissues.

1 October 2017 in Biomaterials
Verified
Journal Article
Closed access
SESyed Faaiz Enam
Syed Faaiz Enam
JKJack R. Krieger
Jack R. Krieger
TSTarun Saxena
Tarun Saxena
BWBrian E. Watts
Brian E. Watts
COClaire E. Olingy
Claire E. Olingy
RBRavi V. Bellamkonda
Ravi V. Bellamkonda

7 March 2018 in Cureus
Verified
Journal Article
Open access
PDF file
ADAneela Darbar
Aneela Darbar
MWMuhammad Waqas
Muhammad Waqas
SESyed F. Enam
Syed F. Enam
SMShaikh D. Mahmood
Shaikh D. Mahmood
The apparent diffusion coefficient (ADC) sequence is based on the diffusion properties of water molecules within tissues and correlates with tissue cellularity. ADC may have a role in predicting tumor grade for gliomas, and may in turn assist in identifying tumor biopsy sites. The purpose of this investigation was to assess the competence of preoperative ADC values in predicting tumor grades. This was a retrospective investigation. We calculated the ADC values in the areas of greatest restriction in solid tumor components, and we recorded the pattern of contrast enhancement. Pathology reports masked to the imaging results were reviewed independently. We calculated the differences in the mean values of different tumor grades and high-grade and low-grade gliomas. A receiver operator curve (ROC) analysis assessed the predictive potential of ADC values for low-grade gliomas. Forty-eight cases of glioma were included in our study. We noted a statistically significant difference in the lowest mean ADC values for the tumor regions of Grade IV lesions (333.83 ± 295.47) compared with Grade I lesions (653.20 ± 145.07). On ROC analysis, we noted an area under the curve (AUC) of 0.80 for the lowest ADC value in the whole tumor region, which was a predictor of low-grade glioma with 95 % confidence interval (CI) of 0.675-0.926. The sensitivity of the lowest ADC value was 84.5% for high-grade lesions. Given our findings that the means of the lowest ADC value are significantly different between low and high-grade gliomas with an AUC of 0.80 for ADC as a predictor of low-grade lesions and a sensitivity of 84.5% for high-grade lesions, ADC values contain some predictive properties of tumor grading. ADC values may be a valuable parameter in the assessment and treatment of tumors.

23 November 2022 in Science Advances
Verified
Journal Article
Open access
SESyed Faaiz Enam
Syed Faaiz Enam
CKCem Y. Kilic
Cem Y. Kilic
Jianxi HuangJianxi Huang
Jianxi Huang
BKBrian J. Kang
Brian J. Kang
RCReed Chen
Reed Chen
RBRavi V. Bellamkonda
Ravi V. Bellamkonda
Patients with glioblastoma (GBM) have limited options and require novel approaches to treatment. Here, we studied and deployed nonfreezing “cytostatic” hypothermia to stunt GBM growth. This growth-halting method contrasts with ablative, cryogenic hypothermia that kills both neoplastic and infiltrated healthy tissue. We investigated degrees of hypothermia in vitro and identified a cytostatic window of 20° to 25°C. For some lines, 18 hours/day of cytostatic hypothermia was sufficient to halt division in vitro. Next, we fabricated an experimental tool to test local cytostatic hypothermia in two rodent GBM models. Hypothermia more than doubled median survival, and all rats that successfully received cytostatic hypothermia survived their study period. Unlike targeted therapeutics that are successful in preclinical models but fail in clinical trials, cytostatic hypothermia leverages fundamental physics that influences biology broadly. It is a previously unexplored approach that could provide an additional option to patients with GBM by halting tumor growth.

28 August 2015 in British Journal Of Neurosurgery
Verified
Journal Article
Closed access
PDF file
MWMuhammad Waqas
Muhammad Waqas
MSMuhammad Shahzad Shamim
Muhammad Shahzad Shamim
SESyed Faaiz Enam
Syed Faaiz Enam
MQMohsin Qadeer
Mohsin Qadeer
SBSaqib Kamran Bakhshi
Saqib Kamran Bakhshi
KAKhabir Ahmad
Khabir Ahmad
Background Data on the evaluation of the Rotterdam Computed Tomography Classification (RCTS) as a predictor of outcomes in patients undergoing decompressive craniectomy (DC) for trauma is limited and lacks clarity. Objective To explore the role of RCTS in predicting unfavourable outcomes, including mortality in patients undergoing DC for head trauma. Methods This was an observational cohort study conducted from 1 January 2009 to 31 March 2013. CT scans of adults with head trauma prior to emergency DC were scored according to RCTS. A receiver operating characteristic curve analysis was performed to identify the optimal cut-off RCTS for predicting unfavourable outcomes [Glasgow outcome scale (GOS) = 1–3]. Binary logistic regression analysis was performed to evaluate the relationship between RCTS and unfavourable outcomes including mortality. Results One hundred ninety-seven patients (mean age: 31.4 ± 18.7 years) were included in the study. Mean Glasgow coma score at presentation was 8.1 ± 3.6. RCTS was negatively correlated with GOS (r = −0.370; p < 0.001). The area under the curve was 0.687 (95% CI: 0.595–0.779; p < 0.001) and 0.666 (95% CI: 0.589–0.742; p < 0.001) for mortality and unfavourable outcomes, respectively. RCTS independently predicted both mortality (adjusted odds ratio for RCTS >3 compared with RCTS ≤3: 2.792, 95% CI: 1.235–6.311) and other unfavourable outcomes (adjusted odds ratio for RCTS >3 compared with RCTS ≤3: 2.063, 95% CI: 1.056–4.031). Conclusion RCTS is an independent predictor of unfavourable outcomes and mortality among patients undergoing emergency DC.